Seagen Inc (SGEN)
179.33
+5.33 (+3.06%)
USD |
NASDAQ |
Jun 24, 16:00
178.65
-0.68 (-0.38%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 33.01B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 13.93% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 19.63 |
| Price to Book Value | 11.01 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 48.66% |
News
Headline
Wire
Time (ET)
SA Breaking News
06/24 10:38
Yahoo
06/21 13:25
MT Newswires
06/21 10:21
MT Newswires
06/17 17:03
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 07/29/2022* | -- | Results | Q2 2022 | -- | -0.89 | -- | |
| 07/29/2022* | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 04/28/2022 | -- | Results | Q1 2022 | -0.74 | -0.94 | 21.61% | |
| 04/28/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/09/2022 | -- | Results | Q4 2021 | -0.95 | -0.87 | -9.67% | |
| 02/09/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 10/28/2021 | -- | Results | Q3 2021 | -1.61 | -0.57 | -182.5% | |
| 10/28/2021 | 16:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies. |
| URL | https://www.seagen.com |
| Investor Relations URL | https://investor.seagen.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Jul. 29, 2022 (est.) |
| Last Earnings Release | Apr. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 24, 2022.
Fundamentals
| Revenue (TTM) | 1.669B |
| Total Expenses (TTM) | 2.362B |
| Net Income (TTM) | -689.54M |
| Total Assets (Quarterly) | 3.617B |
| Total Liabilities (Quarterly) | 618.23M |
| Shareholders Equity (Quarterly) | 2.998B |
| Cash from Operations (TTM) | -590.49M |
| Cash from Investing (TTM) | 394.26M |
| Cash from Financing (TTM) | 84.65M |
Ratings
Profile
Edit
| Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies. |
| URL | https://www.seagen.com |
| Investor Relations URL | https://investor.seagen.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Jul. 29, 2022 (est.) |
| Last Earnings Release | Apr. 28, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| BBH | 24.19M USD | 5.52% |
| FBT | 55.78M USD | 4.35% |
| HQH | 36.77M USD | 3.31% |
| IBB | 248.29M USD | 3.28% |
| BMEZ | 69.26M USD | 2.74% |
| FBIOX | 122.66M USD | 2.60% |
| POAGX | 237.77M USD | 2.52% |
| SHISX | 166.87M USD | 1.66% |
| POGRX | 134.82M USD | 1.54% |
| VHCOX | 263.77M USD | 1.34% |
| XBI | 88.68M USD | 1.27% |
| CGVHX | 82.71M USD | 0.94% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| SGEN Tweets |